Nnyocha na-egosi na enwere ike iji PixCell's HemoScreen ™ iji nyochaa ihe nlele ọbara nke ọrịa na imezi usoro ọgwụgwọ nke ndị ọrịa nwere ọrịa ọbara.
ILIT, York, Israel, Ọktoba 13, 2020 / PRNewswire/ - PixCell Medical, onye na-eme nchọpụta ngwa ngwa nke ngwọta nyocha n'akụkụ akwa, taa kwupụtara nsonaazụ nke ọmụmụ ọhụrụ e bipụtara na International Journal of Laboratory Hematology N'ihi ya, ọmụmụ ahụ na-egosi na Ụlọ ọrụ HemoScreen™ ihe nyocha ọbara n'akụkụ akwa kwesịrị ekwesị maka nleba anya na njikwa nke ndị ọrịa kansa ọbara na-anata ọgwụgwọ chemotherapy.
Ndị nchọpụta si North New Zealand Hospital, Mahadum Copenhagen, Bispebjerg na Frederiksberg Hospitals na Copenhagen, na Mahadum Southern Denmark tụnyere HemoScreen ™ na Sysmex XN-9000 na 206 vein samples na 79 ọcha cell cell (WBC) capillary bed n'akụkụ. Ihe atụ, ọnụọgụ neutrophil zuru oke (ANC), ọbara ọbara uhie (RBC), ọnụ ọgụgụ platelet (PLT) na hemoglobin (HGB).
"Ndị ọrịa cancer na-enweta ọgwụgwọ chemotherapy kpụ ọkụ n'ọnụ na-enwekarị nhụjuanya ọkpụkpụ siri ike n'ihi ọgwụgwọ ma na-achọ nlekọta mgbe niile maka ọnụọgụ ọbara zuru oke (CBC)," Dr. Avishay Bransky, CEO nke PixCell Medical kwuru."Ọmụmụ ihe a na-egosi na HemoScreen nwere ike ịnye nsonaazụ ngwa ngwa na ntụkwasị obi maka nlele izugbe na ihe nlele pathological.Iji ngwaọrụ a n'ọtụtụ ebe nwere ike iwepụ nleta ụlọ ọgwụ na-adịghị mkpa ma belata oge nlebara anya dị mkpa-maka ndị na-arịa ọrịa na ike ọgwụgwụ.Maka ndị ọrịa, nke a bụ egwuregwu na-agbanwe egwuregwu. "
Ihe omuma a na-egosi na HemoScreen na-eji 40 μl nke venous ma ọ bụ ọbara capillary na obere mkpokọta WBC, ANC, RBC, PLT na HGB iji nye nsonaazụ nyocha ngwa ngwa na nke a pụrụ ịdabere na ya maka nduzi mmịnye ọbara na ọgwụgwọ post-chemotherapy.Ndị otu nyocha ahụ chọpụtakwara na HemoScreen na-enwe mmetụta nke ọma maka ịdepụta ụdị ọrịa ọrịa na sel ndị na-adịghị mma (gụnyere mkpụrụ ndụ ọbara uhie nucleated, granulocytes akabeghị aka, na sel mbụ), ma na-ebelata oge ntụgharị nke nsonaazụ ule.
HemoScreen ™, nke PixCell Medical mepụtara, bụ naanị onye nyocha ọbara ọbara nke FDA kwadoro, emebere maka nlekọta-nlekọta (POC), na-ejikọta cytometry eruba na onyonyo dijitalụ n'otu ikpo okwu.Ihe nyocha hematology nwere obere obere nwere ike mechaa nyocha ọnụọgụ ọbara zuru oke (CBC) n'ime nkeji isii, wee jiri ngwa mkpofu a ga-ejupụta na reagents niile dị mkpa maka nyocha ụlọ nyocha ngwa ngwa, nke ziri ezi na dị mfe.
Ọmụmụ ihe ahụ kwubiri na HemoScreen dabara nke ọma maka ụlọ ọgwụ ndị na-ahụ maka ndị ọrịa nwere obere ma nwee ike dabara maka iji ụlọ.
PixCell Medical na-enye ngwọta nyocha ọbara ozugbo enwere ike ibugharị n'ezie.N'iji teknụzụ na-elekwasị anya viscoelastic nke ụlọ ọrụ na ọhụụ igwe ọgụgụ isi, PixCell's FDA-approved and CE kwadoro HemoScreen diagnostic platform na-ebelata oge nnyefe nke nsonaazụ nchọpụta site na ụbọchị ole na ole gaa na nkeji ole na ole.Site na ntakịrị ntakịrị ọbara, PixCell nwere ike ịnye ọgụgụ ziri ezi nke usoro ọnụọgụ ọbara 20 n'ime nkeji isii, na-azọpụta ndị ọrịa, ndị dọkịta na sistemu ahụike ọtụtụ oge na ọnụ ahịa.
Oge nzipu: Jul-15-2021